Evidence map›Paper›PMID 35167490›Full record

ArticleJCI insight2022

Human antibodies against noncircumsporozoite proteins block Plasmodium falciparum parasite development in hepatocytes.

Amanda Fabra-García, Annie Sp Yang, Marije C Behet, Zen Yap, Youri van Waardenburg, Swarnendu Kaviraj, Kjerstin Lanke, Geert-Jan van Gemert, Matthijs M Jore, Teun Bousema and 1 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Monoclonal antibodies for malaria prevention.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Amanda Fabra-GarcíaRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Annie Sp YangRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Marije C BehetRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Zen YapRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Youri van WaardenburgRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Swarnendu KavirajGennova Biopharmaceuticals Ltd., Pune, India.
Kjerstin LankeRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Geert-Jan van GemertRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Matthijs M JoreRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Teun BousemaRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Robert W SauerweinRadboud University Medical Centre, Department of Medical Microbiology, Nijmegen, The Netherlands.
Radboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sporozoite-based approaches currently represent the most effective vaccine strategies for induction of sterile protection against Plasmodium falciparum (Pf) malaria. Clinical development of subunit vaccines is almost exclusively centered on the circum-sporozoite protein (CSP), an abundantly expressed protein on the sporozoite membrane. Anti-CSP antibodies are able to block sporozoite invasion and development in human hepatocytes and subsequently prevent clinical malaria. Here, we have investigated whether sporozoite-induced human antibodies with specificities different from CSP can reduce Pf-liver stage development. IgG preparations were obtained from 12 volunteers inoculated with a protective immunization regime of whole sporozoites under chloroquine prophylaxis. These IgGs were depleted for CSP specificity by affinity chromatography. Recovered non-CSP antibodies were tested for sporozoite membrane binding and for functional inhibition of sporozoite invasion of a human hepatoma cell line and hepatocytes both in vitro and in vivo. Postimmunization IgGs depleted for CS specificity of 9 of 12 donors recognized sporozoite surface antigens. Samples from 5 of 12 donors functionally reduced parasite-liver cell invasion or development using the hepatoma cell line HC-04 and FRG-huHep mice containing human liver cells. The combined data provide clear evidence that non-CSP proteins, as yet undefined, do represent antibody targets for functional immunity against Pf parasites responsible for malaria.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMalariaMalaria, FalciparumMalaria VaccinesParasitesAnimalsAntibodies, ProtozoanHepatocytesHumansMicePlasmodium falciparumProtozoan ProteinsSporozoitesAntibodies, ProtozoanMalaria VaccinesProtozoan ProteinsImmunoglobulinsInfectious diseaseMalariaVaccines

Identifiers

PMID35167490
PMCPMC8986077
OpenAlexW4213133021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.